RG 3039

Drug Profile

RG 3039

Alternative Names: PF 6687859; PF-06687859; Quinazoline 495; RG3039

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Families of SMA
  • Developer Repligen Corporation
  • Class Small molecules
  • Mechanism of Action DcpS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Spinal muscular atrophy

Most Recent Events

  • 06 Nov 2014 Phase-I development is ongoing in USA
  • 03 Jan 2013 RG 3039 sub-licensed to Pfizer worldwide
  • 26 Sep 2012 Repligen initiates enrolment in a phase Ib trial in healthy volunteers in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top